Thursday, September 3, 2009

Thermo Fisher acquires German diagnostics firm

By Mass High Tech staff

Video Gallery

MHT's Julie Donnelly: Life science startups finding investments

Breaking down the MIT $100K

Innerscope Research sensor vest tests biometric response to visual aids

Related News

Thermo Fisher refinances debt [November 13, 2009]

Thermo Fisher grant program to award RNAi reagents [August 13, 2009]

North Bridge pours $6.5M into Aushon BioSystems [March 31, 2009]

Aushon Biosystems buys Thermo Fisher’s SearchLight unit [March 17, 2009]

Life sciences CEOs line up questions for Obama [January 23, 2009]

Thermo Fisher Scientific Inc., the Waltham-based instrumentation and research products company, has signed a deal to buy in-vitro diagnostics test firm BRAHMS AG for about $470 million. BRAHMS is a German company, with European and U.S. sales offices, that employs 400 people. Upon completion of the acquisition, expected this month, the company will become part of the Specialty Diagnostics unit of Thermo Fisher’s Analytical Technologies Segment.

BRAHMS develops a diagnostic biomarker, called Procalcitonin (PCT), that detects and monitors the treatment of sepsis, a condition of bacterial infestion overtaking a person’s bloodstream.

In April, Waltham-based Thermo Fisher Scientific (NYSE: TMO) announced an agreement to pay about $120 million to buy Biolab Pty. Ltd., the scientific and medical division of Alesco Corp., an industrial brands company in Australia and New Zealand. Biolab develops laboratory equipment, analytical instruments and life science consumables.

The company reported a net profit of $994 million on total revenue of $10.5 billion in 2008, compared to a net profit of $761 million on $9.75 billion in 2007.